Michael Henry Brent

Michael Henry Brent

Auto-generated profile, based on publicly available information

Michael Henry Brent

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada; Department of Ophthalmology, Toronto Western Hospital, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
JBJohnny-Wei Bai
Johnny-Wei Bai
LLLeif Erik Lovblom
Leif Erik Lovblom
MCMarina Cardinez
Marina Cardinez
AWAlanna Weisman
Alanna Weisman
MFMohammed A. Farooqi
Mohammed A. Farooqi
BPBruce A. Perkins
Bruce A. Perkins

1 December 2021 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
OEOluwaseun Egunsola
Oluwaseun Egunsola
LDLaura E. Dowsett
Laura E. Dowsett
RDRuth Diaz
Ruth Diaz
MBMichael H. Brent
Michael H. Brent
VRValeria Rac
Valeria Rac
FCFiona Clement
Fiona Clement

25 January 2016 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JBJohnny W. Bai
Johnny W. Bai
GBGeneviève Boulet
Geneviève Boulet
EHElise M. Halpern
Elise M. Halpern
LLLeif Erik Lovblom
Leif Erik Lovblom
DEDevrim Eldelekli
Devrim Eldelekli
BPBruce A. Perkins
Bruce A. Perkins
Older patients with longstanding type 1 diabetes have high cardiovascular disease (CVD) risk such that statin therapy is recommended independent of prior CVD events. We aimed to determine self-reported CVD prevention guideline adherence in patients with longstanding diabetes. 309 Canadians with over 50 years of type 1 diabetes completed a medical questionnaire for presence of lifestyle and pharmacological interventions, stratified into primary or secondary CVD prevention subgroups based on absence or presence of self-reported CVD events, respectively. Associations with statin use were analyzed using multivariable logistic regression. The 309 participants had mean ± SD age 65.7 ± 8.5 years, median diabetes duration 54.0 [IQR 51.0, 59.0] years, and HbA1c of 7.5 ± 1.1 % (58 mmol/mol). 159 (52.7 %) participants reported diet adherence, 296 (95.8 %) smoking avoidance, 217 (70.5 %) physical activity, 218 (71.5 %) renin-angiotensin-system inhibitor use, and 220 (72.1 %) statin use. Physical activity was reported as less common in the secondary prevention subgroup, and current statin use was significantly lower in the primary prevention subgroup (65.5 % vs. 84.8 %, p = 0.0004). In multivariable logistic regression, the odds of statin use was 0.38 [95 % CI 0.15–0.95] in members of the primary compared to the secondary prevention subgroup, adjusting for age, sex, hypertension history, body mass, HbA1c, cholesterol, microvascular complications, acetylsalicylic acid use, and renin-angiotensin system inhibitor use. Despite good self-reported adherence to general CVD prevention guidelines, against the principles of these guidelines we found that statin use was substantially lower in those without CVD history. Interventions are needed to improve statin use in older type 1 diabetes patients without a history of CVD.

1 April 2019 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
Tina FelfeliTina Felfeli
Tina Felfeli
RARoy Alon
Roy Alon
RMRebecca Merritt
Rebecca Merritt
MBMichael H. Brent
Michael H. Brent

29 July 2011 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
JMJonathan A. Micieli
Jonathan A. Micieli
ETEdmund Tsui
Edmund Tsui
WLWai Ching Lam
Wai Ching Lam
MBMichael H. Brent
Michael H. Brent
RDRobert G. Devenyi
Robert G. Devenyi
CHChris Hudson
Chris Hudson
Purpose: To assess the hemodynamic response of retinal arterioles and venules following a single intravitreal injection of ranibizumab in neovascular age-related macular degeneration (NV-AMD) patients and to assess the influence of the number of prior injections on this response. Methods: Fifteen NV-AMD patients were prospectively recruited and grouped according to the dosage of ranibizumab previously received. Group 1 NV-AMD patients (n = 7) had previously received 1.50 mg or less, and group 2 patients (n = 8) had received more than 1.50 mg in the study eye. A group of 12 non-NV AMD patients were also recruited for control comparison. Vessel diameter, centreline blood velocity and blood flow were assessed with the Canon Laser Blood Flowmeter immediately prior to an injection and at a mean follow-up of 37.7 and 36.7 days for group 1 and group 2 patients, respectively. Results: The NV-AMD patients as a whole and the group 1 cohort had a significantly greater arteriolar diameter at baseline than the non-NV AMD patients. There was a significant reduction in arteriolar diameter, velocity and blood flow in group 1 but not in group 2 NV-AMD patients at follow-up. There was only an insignificant decrease in measured parameters of the retinal venules. At follow-up, there was no difference in the diameter, velocity or flow between AMD patients. Conclusion: Intravitreal ranibizumab treatment for NV-AMD induces a reduction in arteriolar diameter, velocity, and blood flow in patients who have received <1.50 mg of ranibizumab.